


Estonia

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous	s survey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
International units	Factor VIII	0.00	A	3.07	A	3.28	A	4.81
per capita	Factor IX	0.00	A	0.22	_	0.36	•	0.36
Organisation	Comprehensive Care Centres (CCC's)	No		No		No		No
of care	Haemophilia Treatment Centres	No		No		No	A	Yes
	National Haemophilia Council or Co-ordinating Group	No		No		No		No
	Number of groups in decision-making on haemophilia care	0		0	A	2	•	1
	Number of groups choosing haemophilia treatment products	0		0	A	2	•	1
	National Tender for procurement of factor concentrates					No	A	Yes
Treatment	Home Treatment					Yes		Yes
regimens	% of people with haemophilia using home treatment					51-75%	A	76-100%
	Treatment delivered to the patient's home					Some		Some
	Prophylaxis treatment availability					Some		Some
	Children currently on prophy (%)					76-100%		76-100%
	Adults currently on prophy (%)					1-25%	A	26-50%
	Access to ITI (% of people with inhibitors)					1-25%	A	100%
Access to	Emergency medicine and acute surgery					Yes		
specialist services	Paediatrics					Yes		
	Infectious disease specialists (especially HIV)					Yes		
	Hepatology					Sometimes		
	Rheumatology					Sometimes		
	Orthopaedics					Yes		
	Physiotherapy					Sometimes		
	Dentistry					Never		
	Obstetrics and Gynaecology					Sometimes		
	Genetics					Sometimes		
	Social and psychological support					Never		
	Pain management					Sometimes		
	General surgery					Yes		
	Urology					Yes		
Share of Expected	Haemophilia A					71%	A	76%
Bleeding Disorder	Haemophilia B					25%	•	25%
Prevalence	von Willebrand Disease					7%	A	8%
Haemophilia	Pasma-derived factor concentrate			Always		Always		Always
replacement	Recombinant factor concentrate			,		Rarely	•	Always
therapy	Plasma					Always	•	Rarely
· -	Cryoprecipitate					Always	•	Never
VWD replacement	Plasma-derived factor concentrate					Always		Always
therapy	DDAVP					Always	•	Sometimes
1.5	Plasma					Always	•	Rarely
	Cryoprecipitate					Always	_	Never
	- J - 1 1						_	